Once-daily oral maintenance treatment for patients with recurrent ovarian cancer1
ZEJULA is indicated for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy.
Please see Important Safety Information below and full Prescribing Information.
See the pivotal trial data
Results from the phase 3 pivotal trial were published in the December 2016 issue of
The New England Journal of Medicine:
"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer."
Subscription required to view full article.
HEALTHCARE PROFESSIONALS ONLY
Sign up to receive the latest news about ZEJULA.
* Required field